is now

March, 2023

Groningen, The Netherlands

Like many other biopharmaceutical companies, BiOrion has been unable to escape the deteriorating investment climate in pharmaceutical biotechnology over the past year.
However, some founders of BiOrion are convinced that its platform technology of synthetic single-domain antibodies (nanobodies) can lead to many new radiopharmaceuticals for patients with fibrotic diseases, including fibrotic cancers. This technology makes it possible to identify new targets faster, cheaper and better for diseases that cannot yet be optimally treated.
That is why we have decided to acquire assets and knowhow from BiOrion and transfer them to our new company Cortalix.

With Cortalix, we will further expand our pipeline of novel PET imaging diagnostics and targeted radiotherapeutics and build partnerships with pharmaceutical companies using our synthetic single-domain antibody platform.